
Keywords: CAD; coronary artery disease; CHM; Chinese herbal medicine; CI; confidence interval; COPD; chronic obstructive pulmonary disease; EGFR-TKIs; epidermal growth factor receptor tyrosine kinase inhibitors; GMP; Good Manufacturing Practice; HR; hazard ratio; I